Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00266760 · ClinicalTrials.gov registry record
Characteristics of Episodic Ataxia Syndrome
A clinical trial, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 39
- Enrollment target
NCT00266760: Completed study, sponsored by University of California, Los Angeles.
NCT00266760 is a clinical trial that has completed, run by University of California, Los Angeles. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00266760 has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 39 participants
- Enrollment target
Study Summary
Episodic ataxia (EA) is a rare genetic disease characterized by episodes of imbalance, incoordination, and slurring of speech. The underlying cause of EA is only partly understood, and currently there are no established treatments. There is also little information about the link between EA's clinical features and its genetic basis. The purpose of this study is to better characterize EA and disease progression. In turn, this may direct the development of future treatments.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2006-05 |
| Est. Completion | 2011-07 |
What the finished NCT00266760 record still lists
NCT00266760 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00266760 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00266760 about?
NCT00266760 is a clinical study titled "Characteristics of Episodic Ataxia Syndrome". Episodic ataxia (EA) is a rare genetic disease characterized by episodes of imbalance, incoordination, and slurring of speech. The underlying cause of EA is only partly understood, and currently there are no established treatments. There is also little information about the link between EA's clinica...
What is the current status of trial NCT00266760?
This trial is currently completed. The enrollment target is 39 participants. The study started on 2006-05. Estimated completion is 2011-07.
Who is sponsoring clinical trial NCT00266760?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia